血糖自己測定に使う検査薬のOTC化を検討した、厚生労働科学研究班の報告書が公表されました。
A report by a Health and Labour Sciences Research group examining the conversion of blood glucose self-monitoring test strips to over-the-counter status has been published.
ここで、素朴な疑問があります。測定器も検査薬も現在すでに買えるのに、なぜ一般用検査薬へ転用するのでしょうか。OTCになれば安くなるのでしょうか。
This raises a simple question. Since both meters and test strips can already be purchased, why convert the strips to over-the-counter diagnostic tests? Would they become cheaper if they were sold as OTC products?
今回の中心は、「初めて買えるようにすること」ではありません。変わるのは、誰が、何のために使う製品として承認するかです。
The central issue here is not making the products purchasable for the first time. What would change is who the products are approved for and for what purpose.
「買える」と「一般用として使える」は違う
“Available to buy” and “approved for general-public use” are different
現在の自己血糖測定用検査薬は医療用の体外診断用医薬品です。ただし、処方箋がなければ一般の人に販売できない、という意味ではありません。部会議事録では、業界団体から、測定器と検査薬が許可を持つ薬局等で既に提供されているとの説明がありました。2025年の部会取りまとめも、血糖自己測定の物品がネット等で広く提供されている実態に言及しています。
Current blood glucose self-monitoring test strips are in vitro diagnostic products for medical use. However, this does not mean they cannot be sold to members of the general public without a prescription. In the subcommittee meeting minutes, an industry association explained that meters and test strips are already supplied through licensed pharmacies and similar outlets. The subcommittee’s 2025 conclusions also referred to the fact that blood glucose self-monitoring supplies are widely available online and through other channels.
違うのは、承認区分とそこで想定される使用場面です。
The difference lies in the approval category and the circumstances of use envisaged within it.
現在の医療用検査薬
Current medical-use test strips
患者自身が測定し、主に糖尿病などの経過観察に使う
個別製品の添付文書は、糖尿病の治療管理を医師の指導下で行うよう求める
医療用としての説明と注意事項を持つ
Patients take their own measurements, mainly to monitor the course of diabetes and similar conditions
Individual products’ package inserts require diabetes treatment management to take place under a physician’s guidance
They carry explanations and precautions for medical use
検討中の一般用検査薬
Over-the-counter test strips under consideration
未診断者を含む一般の生活者が自ら選んで使う
「自らの健康管理の指標」として使うことを想定する
一般使用者向けの説明、結果の読み方、受診目安が必要になる
Members of the general public, including people without a diagnosis, choose and use them themselves
Their intended use is as “an indicator for personal health management”
Explanations for general users, guidance on interpreting results, and indications for seeking medical care would be needed
一般用化の意義があるとすれば、流通している物を別の棚へ移すことではありません。未診断者を含む生活者が健康管理目的で使う場面を正式に位置づけ、その人たちに必要な説明と受診への接続を承認・販売の仕組みに入れることです。
If conversion to over-the-counter status has value, it is not a matter of moving products already in circulation to another shelf. It would formally establish their use for health management by members of the general public, including people without a diagnosis, and incorporate the explanations they need and connections to medical care into the approval and sales framework.
ただし、厚労省の一般用検査薬ガイドラインは案の段階です。研究班の提案も、制度決定や個別製品の承認ではありません。
However, the Ministry of Health, Labour and Welfare’s guidelines for over-the-counter diagnostic tests are still in draft form. The research group’s proposals are also neither a finalized policy decision nor approval of any individual product.
何も持っていない人は一式が必要
Anyone starting with no equipment needs a complete set
実際の血糖自己測定には、四つの機能要素があります。
In practice, blood glucose self-monitoring involves four functional components.
数値を表示する測定器本体
その機種に対応する使い捨て検査薬
指先を刺す穿刺器具
穿刺器具に装着し、測定ごとに交換するランセット
The meter itself, which displays the reading
Disposable test strips compatible with that model
A lancing device for pricking the fingertip
Lancets fitted into the lancing device and replaced for each measurement
製品によって一部がセットでも、本体だけでは測れません。今回の一般用化の中心は検査薬です。初めて使う人は、対応する測定器と採血用具もそろえる必要があります。
Even if some components are bundled with a product, the meter alone cannot take measurements. The focus of this proposed OTC conversion is the test strips. First-time users also need a compatible meter and blood-sampling equipment.
研究班の生活者調査では、血糖自己測定の経験者301人中146人、48.5%が、薬局、ドラッグストア、インターネット等で自費購入した経験を答えました。自費購入者146人の検査薬購入先は、調剤併設ドラッグストア64人、調剤薬局63人、インターネット50人でした。複数回答なので重なりがあります。
In the research group’s consumer survey, 146 of the 301 people with experience of blood glucose self-monitoring, or 48.5%, reported having purchased supplies out of pocket through pharmacies, drugstores, the internet, or similar channels. Among these 146 out-of-pocket purchasers, 64 had bought test strips at drugstores with dispensing services, 63 at dispensing pharmacies, and 50 online. Multiple responses were allowed, so these groups overlap.
この調査は、買いたかったのに買えなかった人、店舗までの距離、在庫切れ、地域差を調べていません。「現行制度では入手しにくいから一般用化が必要」とは言えません。
The survey did not examine people who wanted to buy supplies but could not, distances to stores, stock shortages, or regional differences. It does not justify saying that OTC conversion is needed because the products are difficult to obtain under the current system.
OTCになれば安くなるのか
Would OTC conversion make them cheaper?
研究班の薬剤師調査では、「価格」が販売時の課題として最も多く選ばれました。糖尿病患者について54.5%、健診高血糖指摘・未診断者について48.5%、低リスク・健康関心層について47.5%です。
In the research group’s pharmacist survey, “price” was the most frequently selected issue when selling the products. The proportions were 54.5% for people with diabetes, 48.5% for people without a diagnosis who had been told at a health checkup that their blood glucose was high, and 47.5% for low-risk people interested in their health.
ただし、これは薬剤師が価格を課題と考えた割合です。実売価格、利用者が負担した金額、価格を理由に購入を断念した人数、一般用化後の想定価格は調べていません。
However, these are the proportions of pharmacists who considered price an issue. The survey did not examine actual retail prices, the amounts users paid, the number of people who gave up purchasing because of price, or projected prices following OTC conversion.
一般用化は値下げの制度ではなく、OTCは原則として自費購入です。流通や競争で価格が変わる可能性はあっても、安くなる保証はありません。保険診療で測定器の貸与や検査薬等の給付を受けている人では、OTC購入が負担軽減になるとも限りません。
Conversion to OTC status is not a price-reduction policy, and OTC products are generally purchased out of pocket. Distribution and competition might change prices, but there is no guarantee that prices would fall. For people who receive loaned meters or supplies such as test strips through insured medical care, purchasing OTC products would not necessarily reduce their financial burden.
調査で具体的に見えたのは、買った後の問題
The concrete problems identified by the survey concerned what happens after purchase
購入・貸出時に「自分で測った値の解釈」の説明を受けた人は301人中61人、20.3%。「困ったときの医療機関への受診案内」は42人、14.0%でした。
Of the 301 respondents, 61, or 20.3%, said they received an explanation of “how to interpret readings taken by themselves” when purchasing or borrowing supplies. Forty-two, or 14.0%, received “guidance on visiting a medical institution when problems arise.”
一方、不明点や困りごとがあった172人では、針や検査薬の廃棄方法77人、機器や検査薬の扱い68人、採血方法65人などが挙がりました。測定値の理解や、受診すべきかの判断に困った人もいました。
Meanwhile, among the 172 people who had questions or difficulties, 77 reported problems with disposing of needles and test strips, 68 with handling the equipment or test strips, and 65 with taking blood samples, among other issues. Some also had difficulty understanding readings or deciding whether to seek medical care.
調査で具体的に確認できたのは、値の解釈や受診案内の説明を受けたと答えた人が少なく、操作・廃棄・判断の困りごとも報告されたことです。説明を受けなかった全員に同じ説明が必要だったとは限りません。ただし、説明や廃棄、医療機関との連携の多くは、一般用化を待たず、現在の販売でも改善できます。
What the survey specifically established was that few respondents said they had received explanations about interpreting readings or seeking medical care, and that difficulties with operation, disposal, and decision-making were also reported. Not everyone who did not receive an explanation necessarily needed the same explanation. However, many aspects of explanations, disposal, and coordination with medical institutions can be improved in current sales practices without waiting for OTC conversion.
現行制度の改善だけではできないのは、未診断者を含む生活者による健康管理目的の使用を、一般用検査薬として正式に承認することです。この違いに、どこまで追加価値があるのかが問われます。
What improvements to the current system alone cannot do is formally approve the products as over-the-counter diagnostic tests for health-management use by members of the general public, including people without a diagnosis. The question is how much additional value this difference would provide.
37.2%と41.1%が示す範囲
What 37.2% and 41.1% do and do not show
報告書の37.2%は、一般人口の購入意向ではありません。測定経験者301人への複数回答で、112人が「糖尿病予防を目的とした血糖値の把握」を使用目的として選んだ割合です。予防目的で使った人がいたことは示しますが、予防効果は示しません。
The report’s figure of 37.2% is not a measure of purchase intention in the general population. In a multiple-response question to 301 people with measurement experience, it is the proportion represented by the 112 who selected “understanding blood glucose levels for the purpose of diabetes prevention” as a reason for use. It shows that some people used the products for prevention purposes, but it does not demonstrate a preventive effect.
41.1%は、高い値が出た経験のある107人中44人が受診しなかった割合です。高値の基準や測定条件、通院状況は不明で、OTC化の前後比較でもありません。「OTC化すると41.1%が受診しない」とは言えません。
The figure of 41.1% is the proportion of the 107 people who had experienced a high reading represented by the 44 who did not seek medical care. The threshold for a high reading, measurement conditions, and whether respondents were already receiving outpatient care are unknown, and this was not a before-and-after comparison of OTC conversion. It does not justify saying that “41.1% will not seek medical care if the products become OTC.”
報告書には群別受診率で人数と割合が合わない箇所もあるため、本稿ではその数字を使いません。
The report also contains places where the numbers of people and percentages for group-specific care-seeking rates do not match, so I do not use those figures in this article.
OTC化の意義を、何で判断するか
How should the value of OTC conversion be assessed?
研究班は、既診断者と健診で高血糖を指摘された未診断者を当初の中心とし、低リスクの健康関心層への拡大は慎重に検討する段階導入を提案しました。また、対象別の説明、薬剤師支援、受診導線、価格を含む継続可能な仕組みも必要だとしています。
The research group proposed a phased introduction, initially focusing on people already diagnosed and those without a diagnosis who had been told at a health checkup that their blood glucose was high, with cautious consideration of expansion to low-risk people interested in their health. It also stated that explanations tailored to each target group, pharmacist support, pathways to medical care, and a sustainable framework that takes price into account would be needed.
ここからが筆者としての考えです。
What follows is my view as the author.
現在も自費購入できる以上、一般用化には「さらに買いやすくなる」以上の追加価値が必要です。一般向けの承認と説明によって、必要な受診や標準検査につながったのか。誤安心、受診遅延、過剰測定、不安、継続費用は増えていないか。販売数ではなく、こうした成果と害で評価すべきです。
Since the products can already be purchased out of pocket, OTC conversion needs to offer additional value beyond “making them even easier to buy.” Did approval and explanations for the general public lead to necessary medical care and standard testing? Did false reassurance, delays in seeking care, excessive testing, anxiety, or ongoing costs increase? The policy should be assessed by these outcomes and harms, rather than by sales volume.
私は、一般用化の意義を「買えるようになる」「安くなる」とは説明できないと考えます。問うべきなのは、現在の仕組みで解決できていない何を、一般用化によって初めて改善できるのかです。
I do not think the value of OTC conversion can be explained as “making them available to buy” or “making them cheaper.” The question should be what remains unresolved under the current framework that OTC conversion, specifically, would make it possible to improve.
ここまでの資料を踏まえて、みなさんは血糖自己測定用検査薬のOTC化に、どのような意義があると考えるでしょうか。一般向けの使用目的と説明を正式に整えることに価値を置くのか。それとも、価格、受診への接続、健康上の利益が具体的に示されるまで判断を保留するのか。
Based on the sources discussed so far, what value do you see in converting blood glucose self-monitoring test strips to OTC status? Do you value formally establishing an intended use and explanations for the general public? Or would you reserve judgment until concrete evidence is available on price, connections to medical care, and health benefits?
主な資料
Main sources
※本記事は一般的な情報提供を目的としています。個別の診断、治療、受診の判断は医師・薬剤師などへご相談ください。
Note: This article is intended to provide general information. Please consult a physician, pharmacist, or other appropriate professional about individual decisions on diagnosis, treatment, and seeking medical care.
More from the author
Read on note, or subscribe to the Japanese and English publications on Substack.
Sharing uses the publicly accessible original article URL.
